Merit Medical Systems (NASDAQ: MMSI) reported Q1 EPS of $0.37, $0.01 better than the analyst estimate of $0.36. Revenue for the quarter came in at $238.3 million versus the consensus estimate of $236.53 million.

• Q1 2019 worldwide revenue of $238.3 million, up 17.4% as reported over Q1 2018
• Q1 2019 core revenue on a comparable, constant currency basis* up 10.0% over Q1 2018
• Q1 2019 GAAP EPS was $0.11, compared to $0.10 in Q1 2018
• Q1 2019 non-GAAP EPS* was $0.37, compared to $0.31 in Q1 2018

“Our first quarter results fulfilled our goal of 8-10% core growth by landing on the top side of our projection,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer. “This is particularly pleasing when we consider the training, sales meeting and new-year startup expenses included in this quarter.”

“Although there is substantial uncertainty as to the outcome of the Brexit negotiations, we have prepared for the potential outcomes with our newly operational distribution and training center in Reading, United Kingdom,” Lampropoulos continued. “There are several new products scheduled for introduction in the second quarter that we believe will add to our growth and margins.”

“Our transition of the Becton, Dickinson deal continues on schedule with some of the acquired products now being built in our facility in Tijuana, Mexico,” Lampropoulos said. “The entire transition program is scheduled for completion later this year.”

“The Cianna transition is complete and sales continue to grow according to our expectations,” Lampropoulos continued. “Although the complications of Brexit, consolidation of notified bodies and the new European Medical Device Regulation (MDR) have slowed new product approvals, we anticipate receiving approval of the SAVI SCOUT® for sale in Europe in the near future.”

For earnings history and earnings-related data on Merit Medical Systems (MMSI) click here.